Background: Hereditary angioedema is a rare autosomal dominantly inherited immunodeficiency disorder characterized by potentially life-threatening angioedema attacks. oBjective: We aimed to investigate the clinical and genetic features of a family with angioedema attacks. Methods: The medical history, clinical features and C1-INH gene mutation of a Turkish family were investigated and outcomes of long-term treatments were described. results: Five members had experienced recurrent swellings on the face and extremities triggered by trauma. They were all misdiagnosed as familial Mediterranean fever (FMF) depending on frequent abdominal pain and were on colchicine therapy for a long time. They had low C4 and C1-INH protein concentrations and functions. A mutation (c.1247T>A) in C1-INH gene was detected. They were diagnosed as having hereditary angioedema with C1-INH deficiency (C1-INH hereditary angioedema) for the first time. Three of them benefited from danazol treatment without any significant adverse events and one received weekly C1 esterase replacement treatment instead of danazol since she had a medical history of thromboembolic stroke. study liMitations: Small sample size of participants. conclusion: Patients with C1-INH hereditary angioedema may be misdiagnosed as having familial Mediterranean fever in regions where the disorder is endemic. Medical history, suspicion of hereditary angioedema and laboratory evaluations of patients and their family members lead the correct diagnoses of hereditary angioedema. Danazol and C1 replacement treatments provide significant reduction in hereditary angioedema attacks.
INTRODUCTION
Hereditary angioedema (HAE) is a rare autosomal domi- gene may be involved in the pathogenesis of angioedema. 6, 7 Patients with HAE should be treated both during angioedema attacks and for prophylaxis. The identified mutations were confirmed by independent reactions and by family members' DNA whose samples were specifically sequenced for the exon that was shown to carry a mutation in the index. This is a nonsense mutation in the upstream from the reactive site that may affect mRNA or protein stability. The knowledge about genetic features of Turkish patients having HAE is limited to only one study in which mutation analyses of 10 patients were reported. 1 The results of that study showed five novel mutations consisted of regulatory mutation, initiation codon change, splice mutation, nonsense mutation and 9bp-deletion mutation. Although C1-INH-HAE type I is usually inherited in an autosomal dominant manner, two Turkish families with autosomal recessive inheritance were reported in the literature. 1, 9 In our family cases, the inheritance was autosomal dominant. One of the twin children of the index patient had the mutation and the other did not.
RESULTS

Clinical
The results of our study demonstrated that C1-INH-HAE type I may present with diverse clinical features in patients carrying the same mutation for C1-INH gene. Onset of clinical symptoms and signs of HAE started in a time period ranging between very early years of life to adulthood. Besides, symptoms varied in degree from very mild to severe as defined by different members of the family.
When the proband was correctly diagnosed as C1-INH-HAE type I, the other family members were invited for examination and had the chance of correct diagnoses. Symptoms of HAE include mainly swelling on extremities, abdominal cramps, facial and laryngeal edema. 1, 10 Laryngeal edema without asphyxia was experienced by our patients whereas one older relative had died due to airway obstruction.
As observed in our patients, abdominal attacks are very common in Turkish patients with HAE. 1 In the present study, all patients were first misdiagnosed as having FMF and administered colchicine treatment for years. As expected, patients did not have any benefit from colchicine. Misdiagnosis as FMF was also reported in six of 70 patients in the study of Kesim et al. and a case report from Turkey. 1, 11 Abdominal angioedema without skin swelling is a challenging problem in countries where FMF is an endemic disorder. Abdominal pain in HAE may also mimic acute abdominal disorders, which require urgent surgical procedures. High prothrombin fragment F1 and F2
and D-dimer levels are suggested to support HAE during acute angioedema attacks, which prevent patients from undergoing unnecessary abdominal surgery. 12 Besides, elevated D-dimers in HAE attacks
were not found to be associated with increased thrombotic risk. 13 Overlooking patients with HAE gave rise to a very long lag time for diagnosis -up to 52 years as observed in one of our patients. Taking a detailed personal and familial medical history and suspicion for HAE is the key approach to make a correct diagnosis.
Treatment of C1-INH-HAE type I includes on demand or attack therapy and prophylaxis. The proband in our study was first observed when she was having a severe facial angioedema attack and put on fresh frozen plasma therapy immediately since C1-INH concentrate was not available at the time. Then, she was followed-up by long-term prophylaxis with danazol. Danazol therapy was administered for three patients of the family and very well tolerated. We observed that a minimum dose of danazol could provide a very satisfying disease control. On the other hand, the patients were closely followed for potential adverse events on hormonal status and liver. Danazol may cause hormonal adverse events including virilization, decreased breast size, irregular vaginal bleeding or decreased libido, changes on lipid profiles leading to atherosclerosis, and hepatotoxicity. Cicardi et al. reported that menstrual irregularities were the main adverse events of danazol or danazol and stanozolol combination treatment. 10 Zotter et al. observed that hirsutism was the most common adverse event, however, long-term danazol treatment with the lowest effective dose had resulted only a mild virilizing effect. 14 Bork et al. reported that adverse events including hormonal disturbances, headache, weight gain, depression, and liver adenoma, resulted in discontinuation of therapy in 30 of 118 patients. They concluded that patients should be closely monitored due to the high risk of adverse events. 15 Birjmohun et al.
found no significant risk for atherosclerosis whereas Széplaki et al.
recommended monitoring of lipid profiles to detect any development of early atherosclerosis. 16, 17 In a recent study, no hematological Hepatotoxicity is a well-known adverse event of danazol that may cause development of adenomas, focal nodular hyperplasia, and rarely hepatocellular carcinoma. 19, 20 Risk for hemangioma development increases in patients receiving danazol more than 10 years. Besides, danazol induced adenomas were also observed even after discontinuing the therapy. 19 Hepatocellular carcinoma is detected in very rare cases, especially in individuals treated for more than 10 years with high doses such as >200mg/d. 19 On the other hand, the lowest effective dose of danazol was not found to induce liver injury in HAE patients. 21 According to the World Allergy Organization (WAO) guideline for the management of hereditary angioedema, liver ultrasound is recommended to be performed before danazol therapy, yearly during therapy, and 6 months after ceasing therapy. 22 We observed development of liver hemangioma and hepatosteatosis with normal liver structure in two patients. They were all very satisfied with control of attacks. Patients were recommended to come to their routine follow-up visits since they were on a minimum dose of danazol and switching to tranexamic acid did not work well in one of them.
Androgens have anticoagulant and fibrinolytic effects; however, a possible thrombogenic effect of exogenous androgens is an important concern. Androgens may affect platelet aggregation, coagulation, and facilitate thrombosis. 23 Although the link between thrombosis or premature cardiovascular disease and danazol is still unclear, danazol-induced thrombosis was reported in several cases. [24] [25] [26] Danazol therapy was found to increase activation of coagulation in patients treated for more than two years. 16 Depending on these reports, we did not initiate danazol prophylaxis in one patient having thrombotic cerebrovascular disease. 
CONCLUSION
In the present study, we demonstrated a genetic mutation of C1-INH gene in a Turkish family with HAE and showed that longterm danazol prophylaxis might be effective for disease control.
Patients with HAE may be overlooked in countries where FMF is endemic. Since phenotypic diversity may occur in the same family, clinicians should be aware of the signs and symptoms of HAE and consider it in the differential diagnosis to make an early diagnosis leading to prompt initiation of treatment. q
